SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 755.75+2.5%Nov 21 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Miljenko Zuanic3/24/2017 12:04:36 PM
   of 3559
 
REGN (Regeneration is leading developer, not Sanofi) is advancing anti-PD-1 into P3 mNSCLC:

clinicaltrials.gov

From the inclusion criteria:
<Tumor cells expressing PD L1 above a specific percentage of tumor cells by IHC performed by the central laboratory>
It is SINGLE drug arm for REGN2810 against chemo (PFS as primary)....well, indicate high level of optimisms (probably from MRK data) for this indication.

Future is in I/O combinations, it would be good to know what other candidate (except LAG3) they are considering (based on genomic data from RGC)?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News